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Abstract
Background: The Schistosoma mansoni Venom-Allergen-Like proteins (SmVALs) are members of the SCP/TAPS (Sperm-
coating protein/Tpx-1/Ag5/PR-1/Sc7) protein superfamily, which may be important in the host-pathogen interaction. Some
of these molecules were suggested by us and others as potential immunomodulators and vaccine candidates, due to their
functional classification, expression profile and predicted localization. From a vaccine perspective, one of the concerns is the
potential allergic effect of these molecules.
Methodology/Principal Findings: Herein, we characterized the putative secreted proteins SmVAL4 and SmVAL26 and
explored the mouse model of airway inflammation to investigate their potential allergenic properties. The respective
recombinant proteins were obtained in the Pichia pastoris system and the purified proteins used to produce specific
antibodies. SmVAL4 protein was revealed to be present only in the cercarial stage, increasing from 0–6 h in the secretions of
newly transformed schistosomulum. SmVAL26 was identified only in the egg stage, mainly in the hatched eggs’ fluid and
also in the secretions of cultured eggs. Concerning the investigation of the allergic properties of these proteins in the
mouse model of airway inflammation, SmVAL4 induced a significant increase in total cells in the bronchoalveolar lavage
fluid, mostly due to an increase in eosinophils and macrophages, which correlated with increases in IgG1, IgE and IL-5,
characterizing a typical allergic airway inflammation response. High titers of anaphylactic IgG1 were revealed by the Passive
Cutaneous Anaphylactic (PCA) hypersensitivity assay. Additionally, in a more conventional protocol of immunization for
vaccine trials, rSmVAL4 still induced high levels of IgG1 and IgE.
Conclusions: Our results suggest that members of the SmVAL family do present allergic properties; however, this varies
significantly and therefore should be considered in the design of a schistosomiasis vaccine. Additionally, the murine model
of airway inflammation proved to be useful in the investigation of allergic properties of potential vaccine candidates.
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Introduction
Schistosomiasis is an important parasitic disease, caused by
trematode worms of the genus Schistosoma, affecting more than 200
million people worldwide, with a further 650 million individuals
living at risk of infection, remaining a major public health problem
in many developing countries [1]. Transmission occurs through
human contact with water containing the cercariae, the infective
larval stage. These penetrate the skin, maturing into schistosom-
ula, which reach the lungs via the systemic circulation. In the
lungs, the young parasites undergo morphological transformations,
gathering in the portal system, where they mature into adult
worms. After pairing, the onset of egg deposition in the intestinal
lumen, leads to a range of morbidities, such as granulomatous
inflammation and periportal fibrosis [2]. A fraction of the eggs is
eliminated with excreta, reaching the fresh water supply, where
the miracidia hatch, infecting Biomphalaria snails. From these
intermediate hosts the cercariae are released into the water to
infect the definitive human host, closing the cycle [3].
Within the publication of the transcriptome data for Schistosoma
mansoni, a series of novel genes/proteins were selected as potential
vaccine candidates based on their functional classification by Gene
Ontology functions, which would indicate their surface exposure
to allow interaction with the host immune system [4]. Among
them, four members of a family of wasp venom allergen orthologs
were identified, raising the question of what benefits would there
be to the parasite in amplifying allergic or other inflammatory
responses in the host interface. Recently, this gene family was
formally named as Schistosoma mansoni Venom Allergen-Like
proteins (SmVALs) and its individual members analyzed concern-
ing the phylogenetic relationships, genomic organization and
mRNA expression profile across the life cycle [5]. This work
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members, with at least 24 members transcriptionally active, which
can be divided into two groups; those with a signal peptide that
may be released and interact with their immediate environment
(group 1), and those without a secretion signal that should play an
intracellular role (group 2) [5]. Since it was the first article to deal
specifically with this schistosome gene family, herein we will follow
their proposed numbering and nomenclature.
Following the transcriptome work, a series of proteomic studies
describing different aspects of schistosome life cycle and biology
were reported [6,7,8,9,10,11,12,13,14], mostly using the sequence
database of the S. mansoni and S. japonicum transcriptomes [4,15], as
well as the recently published genome databases [16,17].
Noteworthy, were the studies on the released proteins (RP) into
the skin during the transition from cercariae to schistosomula
[7,10], since these proteins could be the first ones to be accessible
to the immune system. In one of these studies, three different
members of the previously described wasp venom allergen
orthologs family (SmVAL4, 10 and 18) were identified as potential
immunomodulators [7] and, more recently, SmVAL10 and 18
were characterized as glycosylated secreted proteins after cercarial
transformation [9]. Moreover, in a report using a more accurate
model to mimic cercariae penetrating human skin, SmVAL4 was
detected in the forming tunnels as a secreted protein, 2 hours post
cercariae invasion [8]. In a study integrating the transcriptome
and proteomic data from S. japonicum, several orthologs of this
protein family were identified [11]; worthy of notice, was an
SjVAL ortholog detected in the tegument of schistosomula,
sharing 73% of identity with SmVAL26. Also of interest,
SmVAL6, a group 2 family member, was identified as a
tegument-exclusive protein in a sub-proteome analysis of S.
mansoni [13] (Figure S1).
In schistosomiasis, morbidity and mortality have been associ-
ated with egg deposition, therefore identifying the components of
Egg Secreted Proteins (ESP) is important to understand how these
antigens can regulate the surrounding cytokine environment.
Using the proteomics approach, four different members of the
SmVAL family (SmVALs 2, 3, 5 and 9) were identified as ESP [6].
However, in marked contrast, more recently, no one of these
proteins were identified in egg secretions by another proteomic
study [12], emphasizing how methodological differences can result
in diverse conclusions. An additional proteomic study reinforced
the wide-spread distribution of this family along the life cycle, by
the identification of several different SmVALs (2, 3/23, 9, 15, 26/
28, and 27) released during in vitro miracidium-to-sporocyst
transformation [14]; most of this data are summarized in Figure
S1.
A natural question that emerged from all these studies is the
biological function of these genes in the host-parasite interface.
Some of these molecules were suggested by us and by other groups
as potential vaccine candidates or immunomodulators, due to their
functional classification, expression profile and predicted localiza-
tion [4,5,7,8,9]. Additionally, SmVALs members present sequence
similarity to the hookworm lead vaccine candidate NaASP-2
[18,19,20]. From a vaccine perspective, a major concern is the
potential allergic effects of these molecules. Herein, we tried to
investigate the immunomodulatory properties of some SmVALs
by exploring the murine model of airway inflammation [21]. The
investigation of localized inflammation in tissues is often difficult
because it is hard to isolate the immune response against a
particular stimulus. Therefore, the utilization of an inflammatory
model in a confined location can be useful to monitor changes in
cell population and to identify regulatory mechanisms.
We selected SmVALs from group 1, which would be putatively
expressed in intra-host stages preferably exposed to interaction
with the immune system. Therefore, we selected SmVAL4, which
would be released in the transition between cercariae and
schistosomula [7,8] and SmVAL26, which would probably be in
the tegument of schistosomula due to its S. japonicum ortholog
identification in the tegument [11]. The respective recombinant
proteins were obtained in an eukaryotic expression system and the
purified proteins used to produce specific antibodies. The protein
expression profile was characterized across the life cycle stages.
The allergic properties of SmVAL4 and SmVAL26 proteins were
investigated in the murine model of airway inflammation. Our
results show that the allergic properties of these molecules vary




Schistosoma mansoni adult worms (BH strain) were obtained by
perfusion of hamsters, 6 weeks after infection with 200 cercariae;
eggs were extracted from infected hamster liver by maceration and
partial digestion with collagenase followed by washes and passage
through sieves and percoll gradients as previously described [22];
miracidia were obtained by exposing purified eggs to a bright light;
cercariae were harvested from infected B. glabrata snails exposed to
light. Following in vitro transformation of cercariae, schistosomula
were cultured for 0–6 hours or 7 days prior to recovery [23].
Ethics statement
The procedures involving animals were carried out in
accordance with the Brazilian legislation (11790/2008). All
animals were handled in strict accordance with good animal
practice and protocols were previously approved by the Ethical
Committee for Animal Research of Butantan Institute, under the
license number 604/09.
DNA constructs
Genes redesigned, optimized and synthesized. The
published DNA sequence of SmVAL4 and SmVAL26 encoding
the predicted proteins [5], were redesigned excluding the signal
Author Summary
The Schistosoma mansoni Venom Allergen Like proteins
(SmVALs) have been identified in the Transcriptome and
Post-Genomic studies as targets for immune interventions.
Two secreted members of the family were obtained as
recombinant proteins in the native conformation. Anti-
bodies produced against them showed that SmVAL4 was
present mostly in cercarial secretions and SmVAL26 in egg
secretions and that only the native SmVAL4 contained
carbohydrate moieties. Due to concerns with potential
allergic characteristics of this class of molecules, we have
explored the mouse model of airway inflammation in order
to investigate these properties in a more confined system.
Sensitization and challenge with rSmVAL4, but not
rSmVAL26, induced extensive migration of cells to the
lungs, mostly eosinophils and macrophages; moreover,
immunological parameters were also characteristic of an
allergic inflammatory response. Our results showed that
the allergic potential of this class of proteins can be
variable and that the vaccine candidates should be
characterized; the mouse model of airway inflammation
can be useful to evaluate these properties.
SmVALs Induce Differential Allergic Responses
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(https://www.dna20.com/) using DNA2.0 optimization algorithms
for expression in Pichia pastoris (Table S1). The fragments
corresponding to the mature protein sequences for SmVAL4
(from K22 to E181) and SmVAL26 (from K25 to K176) were
digested with EcoRI and XbaI to generate insertswith overhang ends
that were purified and cloned into the same sites for the expression
vector pPICZaA (Invitrogen), to produce a protein that contained a
C-terminal hexa-Histidine tag. The resulting constructs were
sequenced to confirm their identity.
Post-translational modification prediction
The signal peptide prediction was performed using the SignalP
3.0 server (http://www.cbs.dtu.dk/services/SignalP/), N-glycosyl-
ation sites were analyzed using the NetNGlyc 1.0 (www.cbs.dtu.
dk/services/NetNGlyc/), O-glycosylation sites were analyzed
using the OGPET (http://ogpet.utep.edu/OGPET/), and trans-
membrane helices were analyzed by TMHMM version 2.0
(http://www.cbs.dtu.dk/services/TMHMM-2.0/). Molecular weight
(MW) and isoelectric point (pI) were calculated with the Compute pI/
Mw tool (http://www.expasy.ch/tools/pi_tool.html).
Expression of rSmVAL4 and rSmVAL26 in Pichia pastoris
The plasmids containing SmVAL4 (optimized sequence) and
SmVAL26 (optimized sequence) were linearized with SacI and the
P. pastoris strain GS115 (Invitrogen) was transformed by electro-
poration following the instructions of the manufacturer. Twenty
colonies were first isolated and purified in YPDS plates containing
100 mg/mL Zeocin, to select putative multi-copy recombinants in
YPDS plates containing 500, 1000, and 2000 mg/mL Zeocin. To
verify production of the relevant proteins, initial studies were done
in small-scale expression conditions, followed by Western blot with
anti-His-tag antibody (GE).
Fermentation conditions were carried out as per manufacturer’s
recommendations. Briefly, selected P. pastoris cells were grown in
15 mL of BMGY 28–30uC in a shaking incubator (250–300 rpm)
until cultures reached an OD600=2.0 (approximately 16–18 h).
The cells were harvested by centrifuging at 30006g for 5 min at
room temperature, the supernatant was decanted and cells
resuspended in 20 mL of BMMY medium to induce expression.
Methanol was added to a final concentration of 0.5% methanol
every 24 h to maintain induction; expression was monitored at 48
and 96 h time points. The supernatants and cell pellets for 15
colonies of each SmVAL was analyzed for protein expression by
Western blot. Those colonies that presented the highest expression
level were selected for scale-up fermentation.
Purification of rSmVAL4 and rSmVAL26 from P. pastoris
For protein expression and purification, selected clones for
SmVAL4 and SmVAL26 were grown (28uC, 250 rpm) in 25 mL
of BMGY in a 250 mL baffled flask until OD600=2.0
(approximately 18 h), then inoculated in 300 mL of BMGY in
a 2.0 L baffled flask and grown in the same conditions until
culture reached OD600=226. The cells were harvested (30006
g, 5 min at room temperature) and resuspended in 600 mL of
BMMY to start induction. Methanol was added to a final
concentration of 0.5% every 24 h to maintain the induction.
Cells were harvested after 48 h (SmVAL26) and 96 h (SmVAL4)
by centrifugation. The culture medium containing the secreted
proteins (rSmVAL4 and rSmVAL26) were filtered through a
0.22 mm membrane, and diluted with 3 volumes of equilibration
buffer (50 mM sodium phosphate pH 5.8 (for rSmVAL4) and
pH 7.2 (for rSmVAL26), 150 mM NaCl, 20 mM imidazole). The
recombinant proteins were then purified by metal affinity
chromatography using the Akta Prime system (GE Healthcare)
under native conditions. Briefly, the sample was loaded onto a
Ni
2+-NTA column (5 mL bed volume) pre-equilibrated with the
same buffer. The column was washed with 30 bed volumes of the
equilibration buffer and then eluted with 20–500 mM imidazole
linear gradient. Fractions encompassing the main peak and the
purity of the preparation were assessed by SDS-PAGE. Before its
use the proteins were dialyzed in Phosphate Buffer Saline pH 7.4
(PBS).
Circular dichroism (CD) measurements
CD measurements were carried out on a Jasco J-810
Spectropolarimeter at 20uC equipped with a Peltier unit for
temperature control. Far-UV CD spectrum was acquired using a
1 mm path length cell at 0.5 nm intervals over the wavelength
range from 190 to 260 nm. Five scans were averaged for each
sample and subtracted from the blank average spectra. The
protein concentration was kept at 10 mM in 10 mM sodium
phosphate buffer pH 7.4.
Protein expression profile and N and O-deglycosylation
assays
Total protein extracts from whole parasite stages (eggs,
miracidia, cercariae, in vitro 7-day-old schistosomula and adult
worms) were prepared in 40 mM Tris, pH 7.4, 2% SDS, plus
protease inhibitor cocktail (Sigma) by sonication (4 cycles of 2 min,
with pulses of 0.75 s, 40% amplitude). The samples were
centrifuged at 20,0006g for 30 min at 4uC and the supernatant
was recovered and used for the assays. The tegument extract was
obtained by a freeze/thaw/vortex procedure, as previously
described [24]. Their protein concentrations were determined
with a DC Protein Assay Kit (Bio-Rad, CA, USA). Purified
rSmVALs (50 ng), total parasite protein extracts (20 mg), and total
tegument extract (20 mg) were subjected to SDS-PAGE. The gel
was electroblotted onto a PVDF membrane, which was blocked
with 0.02 M Tris (pH 7.5) and 0.3% Tween 20 containing 5% dry
milk for 16 h at 4uC. Subsequently, the membrane was incubated
in 1:4000 or 1:3000 dilution of anti-rSmVAL4 and anti-
rSmVAL26 primary antibody, respectively, in blocking buffer
plus 150 mM NaCl for 3 h at room temperature. After three
washes using 150 mL of 10 mM Tris (pH 7.5), the membrane was
incubated in a 1:2000 dilution with secondary goat anti-mouse
IgG conjugated to horseradish peroxidase (Sigma) for 1 h,
followed by another three washes using the same buffer. Antibody
reactivity was developed with ECL reagent (GE Healthcare)
according to the manufacturer’s instructions and imaged using
Hyperfilm (GE Healthcare).
N-deglycosylation of native and recombinant proteins was
carried out as previously described [25]. Briefly, 20 mg of parasite
extracts (in 40 mM Tris, pH 7.4, 0.7% SDS, 1% 2-mercaptoeth-
anol) or 10 mg of recombinant proteins (in PBS, pH 7.2, 0.7%
SDS, 1% 2-mercaptoethanol) were denatured by boiling for
10 min. NP-40 (Sigma) was added (1% final concentration), 2 mL
of recombinant N-glycosidase F (500 U/mL) (New England
Biolabs), 20 mM sodium phosphate (pH 7.5) for a final volume
of 20 mL, and incubated overnight at 37uC. For subsequent O-
deglycosylation of native proteins the following enzymes were used
a(2R3,6,8,9) Neuraminidase, O-glycosidase, b(1R4)-Galactosi-
dase and b-N-Acetylglucosaminidase, and the reactions were
carried out as per the manufacturer’s recommendations (Sigma).
Samples of purified rSmVALs and protein parasite extracts
digested and non-digested were submitted to SDS-PAGE. The
gels containing the recombinant proteins before and after
treatment with glycosidases were stained with Schiff’s reagent
SmVALs Induce Differential Allergic Responses
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recommendations; as control for the specificity of the reaction, we
used Bovine Serum Albumin (Bio-Rad) at the same concentration
of the recombinant proteins. To analyze the glycosylation pattern
of native SmVAL proteins, the protein parasite extracts treated
with glycosidases were electroblotted onto a PVDF membrane and
Western blot developed as described above.
Processing cercariae released proteins
Shedding of cercariae from snails was stimulated by exposure to
bright light. Mechanical transformation by vortexing was used to
stimulate the release of gland cell contents of 2000 parasites during
a time course of 0–6 h culture period in 2 mL of RPMI 1640
medium (Invitrogen) containing 300 units/mL penicillin and
300 g/mL streptomycin at 37uCi n5 %C O 2. Parasites were
collected by centrifugation at 2006 ga t4 uC for 5 min and
processed as previously described; the supernatant (medium
containing released proteins) was stored at 220uC with the
addition of 2 mLo f1 0 6 general use protease inhibitor mixture
(Sigma). This soluble preparation, termed the 0–6 h released
proteins (RP), was precipitated with trichloroacetic acid (TCA) and
used for Western blot analysis.
Collection of egg secreted proteins (ESP) and the
hatched fluid (Hf)
For egg released protein collection, eggs were isolated as
previously described [22], followed by a separation of mature and
immature eggs as previously described [26]. ESP was collected by
incubating 3.0 million mature eggs in 10 mL of serum-free RPMI
(Invitrogen) for 72 h at 37uCi n5 %C O 2. Post-culture viability of
eggs was .85%, as assessed by observation of muscular and flame
cell activity in unhatched miracidia. Culture medium containing
ESP was precipitated with TCA and resuspended in 40 mM Tris,
pH 7.4, 2% SDS, plus protease inhibitor cocktail (Sigma) for
Western blot analyses. The Hf was obtained by hatching mature
eggs through exposure to bright light for 1 h in pound water.
Miracidium and egg shell were pelleted by centrifugation at 2006
ga t4 uC for 10 min, and the protein water-soluble content was
carefully collected to avoid turbulence, the sample (Hf) was filtered
through a 0.22 mm polyethersulfone filter (Millipore) and concen-
trated through precipitation with TCA.
Pronase protein digestion
For elimination of the protein moiety, 12 mg of rSmVAL4 was
incubated with 0.05% of pronase (Calbiochem, San Diego, CA)
for 2 h at 37uC. A separate sample of rSmVAL4 was incubated for
2 h at 37uC without pronase to provide an undigested control.
Successful pronase digestion was confirmed by gel electrophoresis
followed by Coomassie staining, which revealed the absence of any
remaining protein (data not shown).
rSmVALs sensitization and challenge
Female BALB/c mice (6–8 wk old) were weight matched and
used throughout this study. To test whether rSmVALs could
induce an inflammatory reaction in the lungs, we adapted the well-
established murine model of asthma based on Ovalbumin (OVA)/
alum sensitizations and challenges [21]. Briefly, mice were
sensitized on days 0, 7 and 14 by subcutaneous (s.c.) injection
(0.4 mL total volume) in the nape of the neck with 10 mg
rSmVALs adsorbed to 2.0 mg of aluminum hydroxide (Alhydro-
gel-Brenntag Biosector). On days 21 and 28, mice were challenged
i.n. with 10 mg of rSmVALs in 50 mL of PBS. Two additional
groups were used: Control group received only the intranasal
challenge with rSmVAL and naı ¨ve mice received only PBS. It is
important to mention that mice were anesthetized intramuscularly
with 100 mL of a solution containing ketamine (Ketamina Agener,
Uniao Quimica Farmaceutica Nacional) and xylazine (Bayer)
before any immunization or challenge, to ensure a complete
instillation to the lungs, as previously described [27].
Bronchoalveolar lavage (BAL)
Twenty four hours after the last challenge, mice were deeply
anesthetized by an i.p. injection of urethane (Sigma-Aldrich) at
15 mg/10 g body weight, the abdominal cavity was opened, and
blood samples from the inferior cava vein were collected for serum
antibody determinations. The trachea was cannulated and lungs
were lavaged twice with 0.5 and 1.0 mL of cold PBS. After total
cell counting, cytospin preparations of bronchoalveolar lavage
(BAL) cells were stained with Instant-Prov (Newprov) and
differential cell counts were performed on 200 cells on the basis
of morphology and staining characteristics. Supernatants from
BAL were collected and frozen at 280uC for cytokines
measurements.
Measurement of rSmVALs-specific IgG1, IgG2a and IgE
antibodies
Anti-SmVALs antibodies were assayed by sandwich ELISA, as
previously described [21]. Briefly, serum samples were titrated for
optimal dilutions for testing different isotypes. For SmVALs-
specific IgE determinations, plates were coated with goat anti-
mouse unlabelled IgE (1:250; BD Bioscience) following the
manufacturer’s recommendations; serum samples were incubated
(1/10 dilution) for 2 h at room temperature and subsequently
biotin-labeled rSmVALs (5 mg/mL) were added to the wells. The
biotinylated rSmVALs were prepared by reacting 1 mL rSmVALs
(1 mg/mL) in PBS with 100 mL of N-hydroxysuccinimidobiotin in
dimethyl sulfoxide (DMSO) (4 mg/mL) for 4 h at room
temperature, followed by overnight dialysis against PBS at 4uC.
The bound rSmVALs-biotin was coupled to streptavidin-peroxi-
dase 1:250, for 15 min incubation at room temperature and
revealed as per the manufacturer’s recommendations. SmVAL-
specific IgE levels of samples were expressed by OD. For
SmVALs-specific IgG1 and IgG2a antibodies, serum samples
were plated on 96-well plates previously coated with rSmVALs
(0.5 mg/well). The bound antibodies were revealed with goat anti-
mouse IgG1 or IgG2a followed by peroxidase-labeled rabbit anti-
goat antibodies (all from Southern Biotech). The concentration of
each specific isotype was estimated by comparison with IgG1 and
IgG2a standards run in parallel and expressed as the mean 6
SEM of the antibody concentration of 4 mice per group.
Cytokine measurements
The cytokine concentration in the BAL fluid was quantified by
ELISA kits specific for IL-5 and IL-10 (BD Biosciences PharMin-
gen) and for IFN-c (Peprotech INC.). The values are expressed as
picograms per milliliter deduced from standards, run in parallel
with the recombinant cytokines. The limit of detection values were
10 pg/mL for IL-5 and IL-10 and 16 pg/mL for IFN-c.
Passive cutaneous anaphylaxis (PCA)
The anaphylactic activity of reactogenic antibodies was
evaluated by passive cutaneous anaphylactic reaction in mice as
described by Ovary et al. [28]. Previously shaved mice were
injected intradermally with 50 mL of three serial dilutions of serum
in each side of the dorsal skin. After 2 h, they were challenged
intravenously with 250 mg of rSmVAL4, rSmVAL4-Pro (Pronase-
SmVALs Induce Differential Allergic Responses
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determinations were made in triplicate and the PCA titers were
expressed as the reciprocal of the highest dilution that gave a lesion
of .5 mm in diameter. The detection threshold of the technique
was established at 1/5 dilutions.
Immunization of mice and polyclonal antibody
production
Polyclonal mouse sera were produced against preparations of
rSmVAL4 and rSmVAL26. BALB/c mice were immunized three
times, subcutaneously in the nape of the neck, at 14-day intervals
with 25 mg of rSmVAL4 or rSmVAL26 formulated with TiterMax
adjuvant (CytRx Corporation; first dose) or PBS 1x (in subsequent
doses). Fifteen days after the last inoculation, rodents were
exsanguinated. The sera were used at a dilution of 1:4000 (anti-
rSmVAL4) and 1:3000 (anti-rSmVAL26) in Western blots.
Statistical analysis
Student’s t-test was used to compare experimental and control
groups on antibody and cytokine levels. For cellular migration
assays and analysis involving more than two groups, statistical
comparisons were performed with one-way ANOVA followed by a
Bonferroni pairwise comparison. A r value,0.05 was considered
statistically significant.
Results
Construction, expression and purification of recombinant
SmVAL4 and SmVAL26
In order to analyze SmVALs that could interact with cells in the
definitive host, we chose 2 members of group 1. SmVAL4 would
be released in the transition between cercaria and schistosomula.
A phylogenetic analysis of SmVALs and SjVALs (Figure S2),
revealed that SmVAL26 branched together with a SjVAL
ortholog, with 73% of identity detected in the tegument of hepatic
schistosomula (Gene Bank accession AAW27353.1)(Figure S3).
SmVALs contain the sperm-coating protein (SCP) signature
sequence (outlined by a dark grey box in Figure 1A) and are
recognized as part of the Pfam SCP family (PF00188) with an E-
value ranging from 6.66610
224 to 8.20610
231. The SmVALs
under investigation, once belonging to group 1, also contain a
putative N-terminal signal peptide (outlined by a grey box in
Figure 1A). Putative N and O-glycosylation sites were identified
and investigated (identified by * and #, respectively in Figure 1A).
The predicted molecular mass and isoelectric points of these
proteins are presented in Table 1.
rSmVAL4 and rSmVAL26
The recombinant proteins rSmVAL4 and rSmVAL26 were
expressed using codon optimization in P. pastoris GS115 strain and
secreted into the culture supernatant (products around 30 kDa
and 20 kDa, respectively) (Figure 1B and 1C). rSmVAL4 and
rSmVAL26 were purified by affinity chromatography on nickel-
charged columns eliminating the main contaminant from both
samples (around 66 kDa) in the flow through (Figure 1B and 1C).
The eluted fractions of rSmVAL4 showed two main bands at ,30
and 34 kDa (Figure 1B lanes 5–8), while rSmVAL26 eluted
fractions presents only one product (,20 kDa) (Figure 1C, lanes
4–7). Eluted fractions were pooled and submitted to extensive
dialysis in PBS pH 7.2; protein yield after dialysis were estimated
to be around 10.0 mg of rSmVAL4/L and 6.0 mg of rSmVAL26/
L of culture. These samples were used in the sensitization and
challenge assays and to generate polyclonal antibodies in mice.
rSmVAL4 and rSmVAL 26 are expressed as glycosylated
proteins
Both Pichia-secreted proteins migrate with a higher molecular
mass than that predicted (,30.0 kDa for rSmVAL4 and ,20 kDa
for rSmVAL26) (Table 1), which could reflect a likely product of
post-translational glycosylation. To test this hypothesis, we
digested the purified proteins with a recombinant N-glycosidase
F, and also stained the gels with Schiff’s reagent to reveal the
presence of glycans. The SDS-PAGE showed that, after digestion,
rSmVAL4 migrated to a lower MW (,25 kDa), demonstrating
the removal of N-glycans (Figure 1D), while rSmVAL26 does not
show any mobility shift (Figure 1F), suggesting that the protein was
not N-glycosylated. Additionally, for both proteins, the Schiff’s
reagent staining procedure revealed the presence of glycans after
treatment with PNGase F, suggesting the presence of a PNGase F
insensitive N-linked glycan site or an O-linked glycosylation site
(Figure 1E and G).
rSmVAL4 and rSmVAL26 present an ordered secondary
structure
Circular dichroism spectra revealed that rSmVAL4 and
rSmVAL26 display an ordered secondary structure, which
resembles the NaASP-2 protein (structure resolved – three layer
a-b-a-sandwich) (Figure 1H), although the proportions of
secondary structure elements (a-helix and b-sheet) were not
calculated.
SmVALs protein expression profile across the parasite life
cycle
Samples prepared from cercariae, schistosomula, adult worms,
eggs and miracidia stages of S. mansoni, and tegument isolated by
the freeze/thaw method, were all separated by SDS-PAGE.
Immunoblotting was performed using mouse anti-rSmVAL4 and
rSmVAL26 antisera. The protein expression profile of SmVALs
revealed a very specific stage associated expression. Briefly, the
expression of SmVAL4 seems to be restricted to the cercariae
stage. In the case of SmVAL26, although we expected it to be in
the tegument due to its similarity with the S. japonicum ortholog, it is
actually detected in the egg, but not in the miracidium stage
(Figure 2A and B). It is important to note that in the assessed
experimental conditions, no sign of cross reactivity was observed
with SmVALs in other stages or in the tegument fraction.
Native SmVAL4 is an N-glycosylated protein
Noteworthy, the SmVAL4 and SmVAL26 native proteins
detected in schistosome extracts migrate with a higher molecular
mass than that predicted (Table 1), which again could reflect a
likely product of post-translational glycosylation. To test this
hypothesis, we digested total cercariae and egg extracts with the
recombinant N-glycosidase F. The immunoblot showed that, after
digestion, the native proteins displayed a shift in the migration,
demonstrating that native SmVAL4 is N-glycosylated, whereas
SmVAL26 is not (Figure 2C and D). In order to investigate
possible O-glycosylations, the extracts were treated with neur-
aminidase, O-glycosidase, beta (1–4) galactosidase, or N-acet-
ylglucosaminidase, all of which had no effect on the proteins’
mobility on SDS-PAGE (data not shown).
SmVAL4 is released by cercariae and SmVAL26 is released
by eggs
To investigate the presence of SmVAL4 in the secretions of
newly transformed schistosomula, we collected the proteins
released by 2000 parasites in a time course manner. We were
SmVALs Induce Differential Allergic Responses
www.plosntds.org 5 February 2012 | Volume 6 | Issue 2 | e1510Figure 1. Expression and purification of rSmVAL4 and rSmVAL26, and characterization of their glycosylations. (A) Schematic
representation of SmVAL proteins used in this study. Highlighted are the putative signal peptide (grey box), the SCP signature sequence (dark grey
box), potential sites for N-glycosylation (*) and O-glycosylation (#), and the cloned region expressed in Pichia pastoris ( ). Numbers correspond
to the amino acid sequence position deduced from the cDNA sequence. (B) SDS-PAGE analysis of fractions from Ni
2+-charged column
chromatography of rSmVAL4 and (C) rSmVAL26; Lanes 5–8 and 4–7, fractions containing the main peak of rSmVAL4 and 26 respectively, eluted by
linear gradient of imidazole (20–500 mM); FT - Flow-through; S – sample. (D) SDS-PAGE of rSmVAL4 and (F) rSmVAL26 stained with Coomassie before
treatment with PNGase F (2) and after digestion with the enzyme (+); (E and G) the same gel was stained with Schiff’s reagent. Positions of molecular
mass standards (kDa) are indicated on the side, 20 mg of protein was loaded in each lane. (H) Circular Dichroism spectra of rSmVAL4 and rSmVAL26
are compared to that of the rNaASP-2 spectra. The CD spectra presented are the averages of five measurements.
doi:10.1371/journal.pntd.0001510.g001
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transformation and its increasing secretion in the medium of
cultured schistosomula from 0–6 h (Figure 3A). However, after
this period, there are still significant amounts of protein within the
parasite or associated to its surface (Figure 3A).
We also evaluated the presence of SmVAL26 in the egg
secretions and in the hatched fluid, using the respective antibody.
SmVAL26 was detected in both extracts (Figure 3B and C).
rSmVAL4 is able to induce airway inflammatory
responses
In order to investigate a putative immunomodulatory effect of
rSmVALs, we explored the well-established murine model of
airway inflammation induced by OVA/Alum sensitization and
OVA intranasal challenge, replacing OVA by the rSmVAL4 and
rSmVAL26 proteins. Our data revealed that mice sensitized and
challenged with rSmVAL4 present an increased number of total
cells in the bronchoalveolar lavage (BAL), when compared with
the control group. This effect comprises mainly an increase in
eosinophils (55%) and macrophages (32%), which resembles an
allergic airway inflammatory response. Mice that received
rSmVAL26 show a discrete increase in total cell counting, mostly
macrophages (Figure 4A and B). When mice received up to 6
doses of rSmVAL26, this profile does not change significantly. The
inflammatory response induced by rSmVALs was also evaluated in
the lungs of mice by histopathology. A dense mixed-cellular
infiltrate surrounding the airway (peribronchovascular inflamma-
tion) was evident only in the group treated with rSmVAL4
(Figure 4D).
Since the allergic effect could be due either to the proteic or the
carbohydrate moieties of rSmVAL4 produced in Pichia pastoris,w e
eliminated the protein moiety by pronase treatment and
performed the sensitization step with the pronase-treated
rSmVAL4 (rSmVAL4-Pro). As shown in Figure 4A and 4E,
pronase treatment of rSmVAL4 totally abolished airway inflam-
mation.
rSmVALs induce specific IgG1, but only rSmVAL4 induces
IgE production
The serum levels of SmVALs-specific IgG1, IgG2a and IgE
were measured in sensitized and challenged mice and in those only
challenged with different rSmVAL proteins. The production of
SmVAL-specific IgG1, a Th2-affiliated antibody isotype, was
significantly higher in all groups analyzed as compared to the
control challenge group (Figure 5A). Additionally, rSmVAL4
showed higher levels of IgG1, and no antibody production was
observed in response to immunization with pronase-treated
rSmVAL4. Concerning the production of SmVALs-specific IgG2a
antibodies, very low levels and no significant differences were
Table 1. Molecular weight and isoeletric point of SmVALs




Native SmVAL4 18.5 29.0 8.68
SmVAL26 17.3 19.0 5.26
Recombinant SmVAL4 21.4 30.0 7.21
SmVAL26 20.2 20.0 5.35
aExp Mw=Expected Molecular weight.
bObs Mw=Approximate Observed Molecular weight.
doi:10.1371/journal.pntd.0001510.t001
Figure 2. Immunoblotting of protein extracts from S. mansoni stages and tegument fraction using anti-rSmVALs polyclonal
antibodies. (A) Anti-rSmVAL4, and (B) anti-rSmVAL26. CER, cercariae; EGG, eggs; MIR, miracidia; AD, adult worms (female and male); SCH, 7-day old
schistosomula; TEG, tegument; (C) Immunoblotting of Cercariae extracts before (2) and after (+) treatment with PNGase F using anti-rSmVAL4; and
(D) Immunoblot of Egg extracts before (2) and after (+) treatment with PNGase F using anti-rSmVAL26 (20 mg of protein was loaded in each lane); P,
positive control rSmVALs (50 ng). Positions of molecular mass standards (kDa) are indicated inside or on the side the autoradiogram film.
doi:10.1371/journal.pntd.0001510.g002
SmVALs Induce Differential Allergic Responses
www.plosntds.org 7 February 2012 | Volume 6 | Issue 2 | e1510detected between experimental and control groups (data not
shown). The serum levels of SmVALs-specific IgE, a Th2 allergic
associated isotype, were also measured, revealing significantly
higher levels only in the rSmVAL4 group as compared to all other
groups (Figure 5B).
rSmVAL4 induces high levels of IL-5 but does not induce
IFN-c or IL-10
We evaluated the secretion of IL-5, IL-10 and IFN-c in the BAL
fluid. The levels of IFN-c were below detectable levels (50 pg/mL)
in all analyzed groups, while the levels of IL-10 did not differ
significantly from the sensitized and challenged groups to those
only challenged (data not shown). The levels of IL-5 were
significantly higher in the rSmVAL4 immunized mice as
compared to the control groups (naı ¨ve or only challenged).
SmVAL4-Pro group revealed intermediate levels of this cytokine,
not differing statistically from control or rSmVAL4 (Figure 6A). It
is important to mention that this IL-5 secretion observed in
SmVAL4-Pro was not sufficient to induce/mediate the eosinophil
infiltration or other parameters of the allergic response.
rSmVAL4 serum is able to cause passive cutaneous
anaphylactic hypersensitivity
Taking into account the eosinophil migration, the presence of
IL-5 in the BAL and the high levels of systemic IgE, we performed
Passive Cutaneous Anaphylactic (PCA) assays to evaluate the
production of anaphylactic IgG1 in heat-inactivated serum of mice
sensitized and challenged with rSmVALs. Our results demon-
strated that IgG1 antibodies produced by the rSmVAL4 group
exhibited strong PCA activity with a very high titer of 1:1250,
whereas in the other groups, including the pronase-treated
rSmVAL4 or the control groups, low levels of anaphylactic IgG1
antibodies were observed (Figure 6B).
rSmVAL4 induces IgE in a conventional protocol of
immunization
The induction of high levels of systemic IgE by rSmVAL4 in the
model of airway inflammation led us to evaluate the use of a less
Th2-prone adjuvant in a conventional protocol of immunization.
Therefore, mice were immunized with rSmVALs formulated in
TiterMax Gold, which is described to produce considerable levels
of IgG2a in addition to IgG1. The rSmVAL4 group showed
higher levels of IgG1 antibody in relation to rSmVAL26.
Concerning the production of SmVALs-specific IgG2a antibodies,
significant levels were detected in both immunized groups as
compared to the control, with no differences between them. The
levels of specific IgG1 and IgG2a and the IgG1/IgG2a ratio
indicate that immunization with TiterMax Gold induced a
predominant Th2 immune response to rSmVAL4 and a more
balanced (Th1/Th2) response to rSmVAL26 (Figure 7A). The
serum levels of SmVALs-specific IgE, were also measured,
revealing significantly higher levels only in the rSmVAL4 group
as compared to all other groups (Figure 7B).
Animals sensitized with rSmVAL4 and rSmVAL26 formulated
in Titermax were also challenged intranasally and airway
inflammation evaluated. It was observed that only the group
receiving rSmVAL4 developed airway eosinophilic inflammation
(data not shown).
Discussion
Recently, SmVALs have emerged from transcriptoma, micro-
array and proteomic studies as potential targets for immune
intervention. In the present manuscript, we extend the previous
molecular characterization performed by Chalmers et al. (2008),
focusing on the protein products of SmVAL4 and SmVAL26,
which may play different roles in the parasite-host interface.
Figure 3. Immunoblotting of released proteins using anti-rSmVALs polyclonal antibodies. (A) Released proteins by newly transformed
schistosomulum (RP) cultured 0–6 h or correspondent parasite extract (PE) hybridized with anti-rSmVAL4 (RP - total released proteins by 1000
parasites was loaded in each lane, PE - 10 mg of protein extract was loaded in each lane). (B) EGG, eggs; MIR, miracidia; Hf, hatched fluid containing
released proteins by hatching eggs, hybridized with anti-rSmVAL26; (C) ESP, secreted proteins by 72 h cultured viable mature eggs, hybridized with
anti-rSmVAL26, (20 mg of protein was loaded in each lane); P, positive control rSmVALs (50 ng).
doi:10.1371/journal.pntd.0001510.g003
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versions of SmVAL4 and SmVAL26 in Pichia pastoris. The
secretion of these proteins in the yeast expression system allowed
purification of the proteins in soluble form. Maybe the most
relevant feature when producing a recombinant protein for
functional assays is its correct folding. Our CD data indicated
that the soluble secreted forms of rSmVAL4 and rSmVAL26
contained an ordered secondary structure, with similar propor-
tions of structural elements (a-helix and b-sheet) as determined for
NaASP-2, which presents a three-layer (a-b-a) sandwich flanked
by an N-terminal loop and a short cystein-rich C terminus [18].
The presence of glycans in such a class of secreted molecules
is somewhat expected. Interestingly, both rSmVAL4 and
rSmVAL26 were revealed to be glycosylated, which could help
the proper folding and stabilization of the protein. It is important
to note though, that the profile of glycosylation obtained in the
Pichia system will not be equivalent to the native pattern in
schistosomes. Concerning the native SmVAL4 protein, we
confirmed the in silico predictions of its N-glycosylation by mobility
shift. On the other hand, the native SmVAL26 was not N-
glycosylated, which is also in conformity with the N-glycan in silico
predictions. We did not detect the presence of O-glycans in the
native SmVALs analyzed. However, we cannot completely
exclude the presence of this class of carbohydrate, since the
deglycosidases used were not specific for schistosomes, which could
have modifications of the core structure, impairing or blocking
enzymatic digestion.
The previously determined mRNA expression profile across the
life cycle suggested that SmVAL4 could be involved in the
invasion of the definitive host [5]; this stage associated expression
was confirmed at the protein level by our Western blot analysis.
SmVAL4 protein was revealed to be present only in the cercarial
stage, increasing in the secretions of newly transformed schisto-
somulum in a time course manner. This data could reflect the fact
that not all parasites were at the same metabolic stage during
transformation or that the protein continues to be released even
after 6 hours post-transformation. The identification of SmVAL4
in cercariae secretions by proteomics suggested that it could be
Figure 4. Evaluation of rSmVALs induction of airway inflammation and lung histopathology. (A) BAL total and differential cell counts for
animals immunized with rSmVAL4 or rSmVAL4-Pro (rSmVAL4 protein after treatment with Pronase) and (B) rSmVAL26. Control group received only
the intranasal challenge with rSmVAL and naı ¨ve mice received only PBS. Results are expressed as means 6 SEM for groups of four mice and are
representative of two experiments. *Significant differences (p,0.05) when compared to Control (mice that were only challenged with the respective
proteins). (C) Lung sections of mice that were only challenged. (D) Representative lung sections of rSmVAL4-induced allergic airway inflammation in
BALB/c mice, revealing the marked infiltration of inflammatory cells in the peribronchiolar space. (E) Lung sections of mice that received rSmVAL4-
Pro, showing patterns similar to the control group; pictures at 106of magnification.
doi:10.1371/journal.pntd.0001510.g004
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significant amount of protein in 6 h schistosomula implies another
localization, which is being investigated by imunohistochemistry
and whole mount in situ hybridization.
Based on its similarity to a S. japonicum ortholog, we predicted
that SmVAL26 could be in the tegument of young adults or
hepatic schistosomula (14 day-old). However, contrary to our
expectations, SmVAL26 was identified in the egg stage and in the
hatched eggs’ fluid. This is in accord with the proteomic study of
Mathieson and Wilson (2010), which compared the contents of
egg, miracidium, egg secretions and hatch fluid. Interestingly, we
also detected SmVAL26 in the secretions of cultured eggs. Based
on our data, we hypothesized that SmVAL26 could be localized in
the egg envelope, or as proposed by Mathieson and Wilson (2010),
in the protective fluid located between the miracidium and the
envelope.
The biological function of SmVALs and orthologs belonging to
the SCP/TAPS domain super-family remains unclear. The
NaASP-2 protein from N. americanus, secreted by the infective
larvae, was described to induce neutrophil recruitment in vivo in
the air pouch model of acute inflammation [29]. Two additional
hookworm SCP/TAPS proteins were reported to have immuno-
modulatory activities. Ancylostoma caninum hookworm platelet
inhibitor (Ac-HPI) exhibits an inhibitory effect on platelet
aggregation, acting via glycoprotein Ia/IIa [30], and A. caninum
neutrophil inhibitory factor (Ac-NIF) showed ability to inhibit
CD11b/18-dependant leukocyte function [31,32]. Concerning the
SCP orthologs from filarial nematodes, the rOv-ASP-1 from
Onchocerca volvulus, showed striking features ranging from angio-
genic activity in mouse corneas, to being proposed as an adjuvant
for bystander proteins due to its ability to bind to APCs and trigger
Th1 proinflammatory cytokines [33]. It is clear that no common
biological function or activity has been associated with this protein
family. And it is possible, as proposed by Hewitson et al. [34], that
the SCP domain operates as an adaptable protein framework
facilitating the evolution of various specialized functions.
In principle, schistosome proteins implicated in the tissue
invasion process, are particularly good candidate antigens for the
development of vaccines and drugs. One major concern on the use
of these and other SmVALs as vaccine candidates is the potential
allergic effects of these molecules. Herein, we have explored the
murine model of airway inflammation, substituting OVA for the
SmVALs, to investigate the putative allergic responses induced by
these proteins. Our results demonstrate that following sensitization
and challenge with the different proteins, they present varying
properties in regards to the recruitment of inflammatory cells to
the BAL fluid. SmVAL4 was shown to induce a marked increase
in total cells in the BAL fluid, mostly due to an increase in
eosinophil and macrophages, which correlated with increases in
IgG1, IgE and IL-5, characterizing a typical allergic response,
while SmVAL26 showed no alterations in the allergic parameters
in the lungs. Furthermore, the use of a Pronase-treated SmVAL4,
strongly supports the conclusion that the allergic properties are
due to the protein itself and not to the carbohydrate moiety. We
also demonstrated that anti-rSmVAL4 sera presented high titers of
anaphylactic IgG1 antibody.
Figure 5. rSmVALs specific antibody production. BALB/c were sensitized s.c. with rSmVALs/Alum, rSmVAL4-Pro/Alum or PBS/Alum (Control)
and then challenged i.n. with the proteins. The experiments were performed 24 h after the last challenge. (A) rSmVALs-specific IgG1 and (B) rSmVALs-
specific IgE were determined in the sera by sandwich ELISA. Results are expressed as means 6 SEM for groups of four mice and are representative of
two experiments. a, b or #, significant differences (p,0.05) when compared to Control group (mice that were challenged with protein only).
doi:10.1371/journal.pntd.0001510.g005
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inhibition of allergies. In this context, the murine model of
ovalbumin induced airway inflammation has been used to
demonstrate that Schistosome infection, egg extracts or some
purified antigens modulate negatively the allergic response
induced by OVA treatment by a mechanism mediated by T
regulatory cells [35,36]. Intrinsic properties of the antigens must
be important for this modulation, since not all molecules modulate
equally the allergic response. It is important to note that our model
is quite different, since we have investigated the allergenic
properties of the antigens per se.
On the other hand, in the course of a S. mansoni infection, two
phases of immune responses have been recognized. In the first 3–5
weeks, during which the host is exposed to immature parasites, the
immune response has been shown to be Th1-predominant. As the
parasites mature, mate and begin to produce eggs at weeks 5–6,
the immune response alters markedly to a strong Th2 profile [37].
However, there are reasons to believe that responses to
schistosome worms during established infections are more
complex. For example, immune responses classically mediated
by the Th2 cytokine IL-5 (eosinophilia and eosinopoiesis) were
reported in the first weeks of infection [38]. Moreover, the
induction of CD4
+ T cells, specific IgE and basophils that produce
IL-4 in response to worm antigens (e.g. SmCB1 – Cathepsin B)
have also been described in this phase [39]. Finally, there is
increasing evidence that excretory/secretory molecules from
schistosome larvae can stimulate a mixed T helper response in
the skin, with evidence of both Th1 and Th2 skewed responses at
the site of infection [40]. Therefore, it is possible that SmVAL4
could be an antigen involved in the initial stage of the infection
inducing a Th2-predominant response, whereas SmVAL26 may
be more important in the late phase of infection.
In a vaccine context, the immunization of mice with rSmVAL4
and TiterMax Gold (a more balanced adjuvant) produced high
levels of IgE in a conventional immunization protocol. It is
interesting to note, that when challenged i.n. after this protocol,
only rSmVAL4 induced airway inflammation (data not shown).
This in itself poses risks, since a vaccination regime that promotes
IgE production may well elicit undesirable side-effects such as
exacerbation of allergy. Furthermore, in a recent report of a
second Phase I trial, adult volunteers did experience allergic
responses following immunization with the Necator ortholog,
NaASP-2 [41]; this data advocates for the presence of IgE
epitopes in this class of molecules. Therefore, it would be
interesting to evaluate the levels of specific IgE antibodies for
SmVAL4 in the sera of individuals resident in a schistosomiasis
endemic area. The IgE epitopes for the SmVAL family remain to
be determined, but it is tempting to conclude that the SmVAL4
protein contains some IgE epitopes absent on SmVAL26. The
functional evaluation of other cercariae secreted SmVALs closely
Figure 6. IL-5 and anaphylactic IgG1 detection. (A) IL-5 production in BAL fluid after sensitization and challenge with different rSmVALs. Results
are expressed as means 6 SEM for groups of four mice and are representative of two experiments. a and b represent statistically significant
differences (p,0.05) between groups. (B) Anaphylactic IgG1 antibodies produced after sensitization and challenge with different rSmVALs; PCA titers
represent the reciprocal of the highest dilution of heat-inactivated plasma that gave a lesion of 0.5 mm in diameter.
doi:10.1371/journal.pntd.0001510.g006
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this model of airway inflammation could help the identification
and mapping of such IgE epitopes.
After the sequencing and assembly of the Schistosoma genome,
efforts in schistosome research should shift from the simple
identification of genes to the characterization of their functions
and interactions with host cells. From this perspective, data
presented here should be taken as a first insight on possible
functions for members of the SmVAL family. They could have an
immunomodulatory role that may be important during parasite
penetration. One could hypothesize that SmVAL4 would be
involved in the recruitment of mast cells and basophils, inducing
secretion of histamine, which could facilitate parasite invasion
through vessel dilatation. Additional studies, such as in situ
hybridization and the evaluation of native proteins should further
elucidate the localization and the role of these proteins.
Finally, we believe that, although the airway inflammation
model explored here presents some divergences from physiological
conditions, it reveals and differentiates the allergic properties of
molecules, proving to be useful for studying molecules with allergic
potential. In selecting SmVAL molecules to be further investigated
as vaccine candidates, we can eliminate those that display allergic
potential in this model, such as SmVAL4.
Supporting Information
Figure S1 Summary of some SmVALs developmental
stage associated mRNA and proteins based on recent
data from S. mansoni and S. japonicum. (A) Upper panel:
the developmental stages of the life cycle of schistosomes; (B)
SmVALs (mRNA or protein) expressed in these developmental
stages. The arrow (q) indicates up-regulation in a particular stage
by Real-time RT-PCR [5,42] or Microarray data [43,44,45]; (N)
Identification of the correspondent SmVAL protein or (N
j) SjVAL by
proteomics data [6,7,8,11,12,13,14]. M and F – male and female
adult worms, * previously reported on the Schistosoma transcriptome
analysis [4], (panel (A) was extracted and modified from [4]).
(PDF)
Figure S2 Phylogenetic analysis of S. mansoni and S.
japonicum VALs protein family, demonstrating that
SjVAL (AAW27353.1) branches with SmVAL26/28 and
27. Phylogenetic trees were inferred by ClustalX 1.83 and
illustrated by Treeview as described in Methods. The S. japonicum
protein GenBank accession numbers are indicated in the tree,
whereas the S. mansoni are the following: SmVAL1 (AAY43180.1),
SmVAL2 (XP_002571733.1), SmVAL3 (AAZ04923.2), SmVAL4
(XP_002571676.1), SmVAL5 (ABB88846.2), SmVAL6 (AAY-
28955.1), SmVAL7 (AAZ04924.1), SmVAL8 (ABW98681.1), Sm-
VAL9 (XP_002582201.1), SmVAL10 (ABO09814.2), SmVAL11
(ABA54555.1), SmVAL12 (XP_002571731.1), SmVAL13 (ABB-
88843.1), SmVAL14 (XP_002569793.1), SmVAL15 (XP_
002582174.1), SmVAL16 (XP_002571817.1), SmVAL17 (XP_
002578833.1), SmVAL18 (XP_002571658.1), SmVAL19 (XP_
002571657.1), SmVAL20 (CAZ28636.1), SmVAL21 (XP_
002578075.1), SmVAL22 (XP_002574629.1), SmVAL23 (XP_
002582175.1), SmVAL24 (XP_002574962.1), SmVAL25 (XP_
002574963.1), SmVAL26 (XP_002577262.1), SmVAL27 (XP_
002577271.1), SmVAL28 (XP_002582199.1) and SmVAL29
(XP_002571340.1).
(PDF)
Figure S3 Alignment of the derived amino acid se-
quence of SmVAL26 and SjVAL26 (AAW27353.1). High-
lighted are the SCP domain (continuous box). The regions with
high identity and similarity between sequences are shown as black
and gray columns, according to the Clustal X algorithm.
(PDF)
Figure S4 Alignment of the derived amino acid se-
quence of SmVAL4, 5, 10, 18, 26, 27 and 28. Demonstration
that SmVAL4, 10 and 18 (all secreted during the cercaria-
schistosomulum transformation process) are more closely related,
whereas SmVAL5, 26, 27 and 28 (all detected in the egg stage) are
more related to each other. The regions with high identity and
similarity between SmVALs are shown as black and gray columns,
according to the Clustal X algorithm.
(PDF)
Table S1 Synthetic genes used in this study.
aRedesigned
sequence using DNA2.0 codon optimization algorithms for
expression in Pichia pastoris.
(PDF)
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